BRIELLYN
Clinical safety rating
cautionComprehensive clinical and safety monograph for BRIELLYN (BRIELLYN).
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) that inhibits gonadotropin secretion, primarily suppressing ovulation and altering cervical mucus and endometrial lining.
| Metabolism | Ethinyl estradiol is metabolized via CYP3A4; norethindrone is metabolized primarily via reduction and conjugation, with CYP3A4 involvement. |
| Excretion | Approximately 60% renal excretion of metabolites, 40% fecal/biliary elimination |
| Half-life | 12-19 hours; clinical context: steady state reached in 3-5 days, dosing adjustment recommended in renal impairment |
| Protein binding | 97-99% bound primarily to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 4-6 L/kg; extensive tissue distribution, crosses placenta and enters breast milk |
| Bioavailability | Oral: 90-100%, minimal first-pass effect |
| Onset of Action | Oral: 1-2 hours; detectable serum levels at 30 minutes |
| Duration of Action | ~24 hours; supports once-daily dosing |
| Molecular Weight | 1006 |
BRIELLYN (ethinyl estradiol / norethindrone) 1 tablet (0.035 mg ethinyl estradiol / 0.5 mg norethindrone) orally once daily at the same time each day.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required. Contraindicated in severe renal impairment or acute renal failure due to potential for fluid retention and hyperkalemia. |
| Liver impairment | Contraindicated in Child-Pugh class B or C hepatic impairment. Use with caution in Child-Pugh class A (mild impairment) with monitoring. |
| Pediatric use | Not indicated for use before menarche. For postmenarcheal adolescents, same dosing as adults: 1 tablet orally daily. |
| Geriatric use | Not indicated for use after menopause. No specific dose adjustment; consider thromboembolic risk and comorbidities. |
| 1st trimester | Contraindicated due to risk of fetal developmental abnormalities including cardiovascular and neural tube defects. |
| 2nd trimester | Contraindicated due to risk of fetal harm; may cause renal agenesis and oligohydramnios. |
| 3rd trimester | Contraindicated due to risk of neonatal complications such as renal failure and skull ossification defects. |
Clinical note
Comprehensive clinical and safety monograph for BRIELLYN (BRIELLYN).
| Placental transfer | Crosses placenta; detected in fetal cord blood and amniotic fluid. |
| Breastfeeding | Excreted into breast milk; potential for serious adverse effects in nursing infants including dehydration and hyperkalemia. Not recommended during breastfeeding. |
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | First trimester: Ethinyl estradiol and norethindrone are contraindicated in pregnancy due to risk of fetal harm, including cardiovascular and limb defects. Second/third trimester: Exposure may increase risk of neonatal withdrawal, jaundice, and fluid retention. |
| Fetal Monitoring | Monitor for signs of thromboembolism, hypertension, and jaundice. In pregnant patients (unintentional exposure), monitor fetal growth, development, and neonatal adaptation. |
| Fertility Effects | No known permanent adverse effects on fertility. Return to baseline ovulation occurs after discontinuation. May mask underlying fertility issues. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from oral contraceptive use. Risk increases with age (especially in women >35 years) and with number of cigarettes smoked. Women who use oral contraceptives should be strongly advised not to smoke.
| Serious Effects |
PregnancyHypersensitivity to any componentAnuriaHepatic impairmentHistory of angioedema with ACE inhibitors or ARBs
| Precautions | Increased risk of thromboembolic disorders, including venous thromboembolism and arterial thrombosis, Risk of myocardial infarction and stroke, especially in smokers and women with hypertension or other cardiovascular risk factors, Hepatic neoplasia (benign and malignant) reported, Gallbladder disease, Carbohydrate and lipid metabolism alterations, Elevated blood pressure, Headache including migraine, Irregular bleeding and amenorrhea, Depression, Carcinoma of the breast and reproductive organs (no conclusive evidence), Decreased effectiveness with concurrent medications like rifampin, anticonvulsants |
| Food/Dietary | No specific food restrictions. Grapefruit juice may increase estrogen levels; avoid excessive consumption. High-fat meals may slightly reduce absorption but not clinically significant. |
| Clinical Pearls | BRIELLYN is a combination oral contraceptive containing ethinyl estradiol and norethindrone. Advise patients to take at the same time daily to maintain consistent hormone levels. Missed doses increase risk of breakthrough bleeding and pregnancy. Counsel on potential decreased efficacy with certain medications (e.g., rifampin, anticonvulsants). Monitor blood pressure at baseline and follow-up due to estrogenic effects. Discontinue if migraine with aura or unexplained vision changes occur. |
| Patient Advice | Take one pill daily at the same time, even if you do not have sex. · If you miss a pill, follow the package instructions or consult your healthcare provider. · Use a backup barrier method (e.g., condoms) for the first 7 days of starting BRIELLYN. · Report severe headaches, vision changes, leg pain, or chest pain immediately. · Do not smoke while taking BRIELLYN, especially if over 35, due to increased risk of blood clots. |
Loading safety data…